Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44196, USA.
Bone Marrow Transplant. 2011 Nov;46(11):1413-7. doi: 10.1038/bmt.2010.314. Epub 2010 Dec 20.
Evidence suggests an advantage for TBI over BU as a component of conditioning regimens for allogeneic hematopoietic cell transplant in patients with ALL. We have employed both TBI and BU for conditioning in ALL and reviewed our experience to compare outcomes. From July 1989 to June 2008, we identified 86-adult ALL patients treated with either a TBI- or BU-based regimen and transplanted with either a well-matched sibling or unrelated donor. Data including demographics, immunophenotype, disease status and cytogenetic risk were examined by Cox proportional hazards analysis. Patients treated with TBI were older (median age 40 vs 33 years; P=0.018), had a higher-risk cytogenetic profile (P=0.010), were more often transplanted using an unrelated donor (P=0.038) and were treated more recently (P<0.001). There was a significant improvement in EFS (P=0.046), and a trend to improved OS (P=0.08) in patients treated with TBI compared with those treated with BU. However, the advantage for TBI could not be confirmed by multivariable analysis where only disease status retained statistical significance.
有证据表明,在 ALL 患者的异基因造血细胞移植的预处理方案中,TBI 优于 BU。我们在 ALL 中同时使用了 TBI 和 BU 作为预处理方法,并回顾了我们的经验以比较结果。从 1989 年 7 月至 2008 年 6 月,我们鉴定了 86 例接受 TBI 或 BU 为基础方案治疗并接受同胞或无关供者移植的成人 ALL 患者。通过 Cox 比例风险分析检查了包括人口统计学、免疫表型、疾病状态和细胞遗传学风险在内的数据。TBI 治疗组患者年龄较大(中位年龄 40 岁 vs 33 岁;P=0.018),具有更高风险的细胞遗传学特征(P=0.010),更常使用无关供者进行移植(P=0.038),并且治疗时间更新(P<0.001)。与 BU 治疗组相比,TBI 治疗组的 EFS(P=0.046)显著改善,OS 有改善趋势(P=0.08)。然而,通过多变量分析,只有疾病状态具有统计学意义,TBI 的优势无法得到证实。